Clinical Scorecard: Laser First: Rethinking Glaucoma Therapy
At a Glance
| Category | Detail |
|---|---|
| Condition | Primary Open-Angle Glaucoma (POAG) and Ocular Hypertension (OHT) |
| Key Mechanisms | Selective laser trabeculoplasty (SLT) delivers energy to the trabecular meshwork to enhance aqueous outflow and reduce intraocular pressure (IOP). |
| Target Population | Patients with newly diagnosed mild-to-moderate POAG or OHT. |
| Care Setting | Clinical settings offering glaucoma management, including ophthalmology practices. |
Key Highlights
- SLT offers a drop-free lifetime of glaucoma care for many patients.
- The LiGHT trial demonstrated lower risks of glaucoma progression and surgery with SLT compared to medical therapy.
- 56% of SLT patients maintained IOP control without further interventions at 6 years.
- SLT is now recommended as first-line therapy by the UK National Health Service and the American Academy of Ophthalmology.
Guideline-Based Recommendations
Diagnosis
- Assess IOP and visual field to diagnose POAG and OHT.
Management
- Consider SLT as the first-line treatment for newly diagnosed POAG and OHT.
Monitoring & Follow-up
- Regular follow-up to monitor IOP and disease progression.
Risks
- Monitor for ocular side effects and adherence issues with medical therapy.
Patient & Prescribing Data
Patients with newly diagnosed mild-to-moderate POAG or OHT.
SLT provides consistent IOP control and reduces the need for medication.
Clinical Best Practices
- Utilize SLT for initial treatment to improve patient adherence and outcomes.
- Educate patients on the benefits of SLT over traditional medical therapy.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.